Standard BioTools Inc. Form 4 Filings

STANDARD BIOTOOLS INC. (LAB) reported that Chief Financial Officer Hanjoon Alex Kim had 28,195 shares of common stock withheld on August 20, 2026 to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units. This was a code F transaction, meaning shares were delivered or withheld for tax payment rather than sold in the open market. After this withholding, Kim directly held 2,534,859 shares of STANDARD BIOTOOLS common stock.

STANDARD BIOTOOLS INC. (LAB) reported that President & CEO Michael Egholm had 97,627 shares of common stock withheld on August 20, 2026 to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units. Following this tax-withholding disposition, he directly holds 6,137,704 shares of common stock.

STANDARD BIOTOOLS INC. President & CEO Michael Egholm reported a tax-withholding disposition of 362,625 shares of common stock on August 3, 2026 at $0.868 per share. The shares were withheld to satisfy tax obligations triggered by vesting restricted stock units granted on August 1, 2025. After this transaction, Egholm directly owns 6,235,331 common shares.

STANDARD BIOTOOLS INC. Chief Financial Officer Kim Hanjoon Alex reported a tax-withholding disposition of 202,476 shares of common stock on July 23, 2026, at $0.895 per share to satisfy tax obligations from vested restricted stock units. After this, he directly owned 2,563,054 shares, including 5,000 shares acquired on May 29, 2026 under the Employee Stock Purchase Plan.

STANDARD BIOTOOLS INC. director Carey Thomas D. reported equity compensation grants consisting of restricted stock units and stock options. He received 99,116 RSUs that vest in full on the earlier of June 18, 2027 or one day before the next annual stockholders’ meeting, subject to continued service. Each RSU converts into one share of common stock at vesting. He was also granted stock options for 263,884 shares at an exercise price of $0.8297 per share, vesting in twelve equal monthly installments beginning on July 18, 2026, and expiring on June 18, 2036. Following these awards, he directly holds 344,456 shares of common stock and 263,884 stock options.

Mackay Sean reported acquisition or exercise transactions in this Form 4 filing.

STANDARD BIOTOOLS INC. reported that SVP & Chief Business Officer Sean Mackay received a grant of 500,000 shares of Common Stock in the form of restricted stock units. These RSUs were granted at no cash cost and increase his direct holdings to 1,506,552 shares after the award.

The RSUs vest over time based on continued service: 40% will vest on June 20, 2027 and the remaining 60% will vest on June 20, 2028, so Mackay receives the underlying shares only if he remains with the company through those dates.

STANDARD BIOTOOLS INC. director Frank Witney reported new equity awards that increase his stake in the company. On June 18, 2026, he received 99,116 Restricted Stock Units (RSUs) and a stock option for 175,923 shares with an exercise price of $0.8297 per share.

The RSUs vest in full on the earlier of June 18, 2027 or one day before the next annual stockholder meeting, subject to continued service. The option vests in twelve equal monthly installments beginning July 18, 2026 and expires on June 18, 2036. Following these grants, Witney holds 309,978 common shares directly and 4,225 shares indirectly through a revocable trust, in addition to the new option position.

STANDARD BIOTOOLS INC. director and 10% owner Eli Casdin reported new equity awards and updated holdings in Form 4. He received 99,116 Restricted Stock Units that vest in full on the earlier of June 18, 2027 and one day before the company’s next annual stockholder meeting, with each RSU delivering one share of common stock upon vesting.

Casdin was also granted stock options for 175,923 shares of common stock at an exercise price of $0.8297 per share, expiring on June 18, 2036 and becoming exercisable in twelve equal monthly installments starting July 18, 2026. Following these awards, he holds 3,053,169 shares directly and has additional indirect holdings of 72,100,000 shares through Casdin Partners Master Fund, L.P., 2,744,219 shares through Casdin Private Growth Equity Fund, L.P., and 13,939,637 shares through Casdin Private Growth Equity Fund II, L.P.

STANDARD BIOTOOLS INC. director Troy Cox reported equity awards consisting of restricted stock units and stock options as part of his compensation. He received 99,116 RSUs that vest in full on the earlier of June 18, 2027, or one day before the company’s next annual stockholder meeting, subject to continued service. He also received stock options covering 175,923 shares of common stock at an exercise price of $0.8297 per share, vesting in twelve equal monthly installments beginning July 18, 2026, and expiring on June 18, 2036. Following these awards, he directly holds 475,702 shares of common stock.

STANDARD BIOTOOLS INC. director Eloi Fenel M reported equity awards consisting of restricted stock units and stock options. He received 99,116 RSUs that vest in full on the earlier of June 18, 2027 or one day before the next annual stockholders’ meeting, contingent on continued service. Each RSU converts into one common share at vesting, bringing direct common stock holdings to 335,299 shares after the award. He was also granted a stock option for 175,923 shares at an exercise price of $0.8297 per share, vesting in twelve equal monthly installments beginning July 18, 2026 and expiring on June 18, 2036.

STANDARD BIOTOOLS INC. director Kathy L. Hibbs reported equity awards that increase her stake in the company. On June 18, 2026, she received 99,116 shares of Common Stock as Restricted Stock Units that vest in full on the earlier of June 18, 2027 and one day prior to the next annual stockholders’ meeting, subject to continued service.

She also received a stock option for 175,923 shares of Common Stock at an exercise price of $0.8297 per share, becoming exercisable in twelve equal monthly installments beginning on July 18, 2026, also subject to continued service. After these awards, she directly owns 236,836 shares plus 175,923 stock options.

STANDARD BIOTOOLS INC. Chief Financial Officer Hanjoon Alex Kim reported a routine tax-related share disposition. On May 20, 2026, 18,871 shares of common stock were withheld to cover tax obligations from vesting restricted stock units. After this non-market transaction, he directly holds 2,760,530 shares.

STANDARD BIOTOOLS INC. senior vice president and chief business officer Sean Mackay reported a routine tax-withholding transaction. On May 20, 2026, 25,729 shares of common stock were withheld to satisfy tax obligations arising from vested restricted stock units granted on May 20, 2024, March 21, 2025 and March 20, 2026.

Following this withholding, Mackay directly holds 1,006,552 shares of common stock. This Form 4 reflects compensation-related tax settlement rather than an open-market purchase or sale.

STANDARD BIOTOOLS INC. President & CEO Michael Egholm reported a tax-related share disposition. On May 20, 2026, 97,626 shares of common stock were withheld to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units. These grants were originally awarded on May 20, 2024, March 21, 2025 and March 20, 2026. After this withholding, Egholm directly holds 6,597,956 shares of common stock, indicating this was a compensation- and tax-driven event rather than an open-market trade.

STANDARD BIOTOOLS INC. President & CEO Michael Egholm reported equity compensation activity and related tax withholding transactions. On April 6, 2026, 196,513 restricted stock units converted into the same number of common shares, and 95,014 of those shares were withheld at $0.908 per share to cover tax obligations. Following these events, he directly held 6,695,582 common shares. On March 20, 2026, he also received a grant of 2,345,340 stock options with a $0.9846 exercise price, expiring in 2036, and a separate award of 1,042,373 shares of common stock; both vest in installments over four years.

STANDARD BIOTOOLS INC. reported that SVP & Chief Business Officer Sean Mackay received new equity awards as part of his compensation. He was granted options to buy 612,240 shares of common stock at an exercise price of $0.9846 per share, expiring on March 20, 2036. These options vest over four years, with 1/16 of the underlying shares vesting on May 20, 2026 and the rest in equal quarterly installments, contingent on continued service. He also received 272,107 restricted stock units that follow the same four‑year vesting schedule, each RSU converting into one share of common stock upon vesting. Following the stock grant, his directly held common stock position is 1,032,281 shares.

STANDARD BIOTOOLS INC. Chief Financial Officer Hanjoon Alex Kim reported routine equity compensation activity and related tax withholding. On March 20, 2026, he received 323,173 shares of common stock and a stock option for 727,140 shares at an exercise price of $0.9846, vesting quarterly after May 20, 2026.

On April 6, 2026, 70,183 restricted stock units converted into the same number of common shares. Of these, 21,301 shares were withheld to cover tax obligations from a prior RSU grant, not sold in the market. After these transactions, he directly held 2,779,401 common shares.

Casdin Eli reported acquisition or exercise transactions in this Form 4 filing.

STANDARD BIOTOOLS INC. director and 10% owner Eli Casdin received 52,991 restricted stock units on the company’s common stock at $1.17 per share equivalent. The RSUs vest in four equal 25% installments on the last day of the last month of each fiscal quarter of 2026, conditioned on his continued board service. Casdin elected to receive these RSUs instead of $62,000 in cash compensation for board work. After this grant, he directly holds 2,954,053 common shares or equivalents, and investment funds associated with him hold additional indirect positions through Casdin Private Growth Equity Fund II, L.P., Casdin Private Growth Equity Fund, L.P., and Casdin Partners Master Fund, L.P.

Cox Troy reported acquisition or exercise transactions in this Form 4 filing.

STANDARD BIOTOOLS INC. director Troy Cox reported an award of 57,264 restricted stock units representing common stock on February 26, 2026. These RSUs were valued at $1.17 per share for reporting purposes and bring his directly held stake to 376,586 shares after the grant.

The RSUs vest in four equal 25% installments on the last day of the last month of each fiscal quarter of 2026, conditioned on his continued board service through each vesting date. Cox elected to receive this equity grant instead of $67,000 in cash compensation for his board role.

Carey Thomas D. reported acquisition or exercise transactions in this Form 4 filing.

STANDARD BIOTOOLS INC. director Thomas D. Carey received a grant of 51,282 shares of common stock in the form of restricted stock units valued at $1.17 per share. These RSUs were taken in lieu of $60,000 in cash board compensation and will vest in four equal quarterly installments during 2026, subject to his continued service. Following this grant, his directly held common stock totals 245,340 shares.

STANDARD BIOTOOLS INC. President & CEO Michael Egholm reported a Form 4 showing a tax-related share disposition. On the transaction date, 66,127 shares of common stock were withheld at $1.15 per share to cover tax withholding obligations from vesting restricted stock units. After this tax-withholding disposition, Egholm directly owned 5,551,710 shares of common stock.

STANDARD BIOTOOLS INC. executive Sean Mackay, SVP & Chief Business Officer, reported a tax-related share disposition. On February 23, 2026, 19,661 shares of common stock were withheld at $1.15 per share to cover tax obligations from previously granted restricted stock units that vested. After this withholding, Mackay directly holds 760,174 shares of Standard BioTools common stock. This was a tax-withholding disposition, not an open-market purchase or sale.

STANDARD BIOTOOLS INC. Chief Financial Officer Hanjoon Alex Kim reported a tax-related share disposition. On the vesting of restricted stock units, the company withheld 12,740 shares of common stock at $1.15 per share to cover tax obligations. After this withholding, Kim directly owns 2,407,346 common shares, which includes 5,000 shares acquired on November 28, 2025 under the employee stock purchase plan.

STANDARD BIOTOOLS INC. (LAB) received a Form 4 reporting open-market stock purchases by Casdin-affiliated investment entities, which are both directors and 10% owners. On 11/24/2025, they bought 150,000 shares of common stock at a weighted average price of $1.4325 per share. On 11/25/2025, they bought an additional 7,550,000 shares at a weighted average price of $1.3031 per share.

Following these transactions, one indirect holding line shows 71,750,000 shares beneficially owned, with ownership attributed to Casdin Partners Master Fund, L.P. and related entities. The filing also reports 2,901,062 shares held directly by Eli Casdin and additional indirect holdings of 13,939,637 and 2,744,219 shares through other Casdin-managed funds, reflecting a sizable continuing stake in LAB.

Standard Biotools Inc. (LAB) reported an insider equity transaction by its President & CEO and director, Michael Egholm. On 11/20/2025, the company withheld 63,529 shares of common stock at $1.28 per share to cover tax withholding obligations that arose when previously granted restricted stock units vested. After this tax withholding transaction, Egholm beneficially owned 5,617,837 shares of Standard Biotools common stock directly.

Standard Biotools Inc. (LAB) reported an insider equity transaction by its Chief Financial Officer on 11/20/2025. The Form 4 shows that 12,739 shares of common stock were withheld at a price of $1.28 per share to cover tax obligations arising from the vesting of restricted stock units previously granted on May 20, 2024 and March 21, 2025. After this tax withholding transaction, the reporting person beneficially owns 2,415,086 shares of Standard Biotools common stock, held directly.

Standard BioTools Inc. (LAB) executive Sean Mackay, SVP & Chief Business Officer, reported a routine equity transaction on Form 4. On 11/20/2025, 19,661 shares of common stock were withheld at a price of $1.28 per share, indicated by transaction code "F," to cover tax obligations arising from the vesting of previously granted restricted stock units. After this tax withholding, Mackay beneficially owns 779,835 shares of Standard BioTools common stock directly.

Standard BioTools Inc. (LAB) large shareholder and director-affiliated entities managed by Eli Casdin reported open-market purchases of common stock. On 11/18/2025, they bought 275,000 shares at a weighted average price of $1.2342, followed by 350,000 shares at $1.2826 on 11/19/2025 and 450,000 shares at $1.3028 on 11/20/2025.

After these transactions, one indirect holding line shows 64,050,000 shares of LAB common stock, with other lines reporting 2,901,062 shares directly and additional indirect positions of 13,939,637 and 2,744,219 shares. The filing explains that various Casdin funds hold these positions and that Eli Casdin and related entities may be deemed to beneficially own the securities through their advisory and general partner roles, while each reports ownership only to the extent of its economic interest.

Standard BioTools Inc. (LAB) reported insider open-market purchases of its common stock by Casdin-affiliated investment entities that are directors and 10% owners. On 11/13/2025, they bought 450,000 shares at a weighted average price of $1.2031 per share. On 11/14/2025, they bought another 250,000 shares at a weighted average price of $1.2392, and on 11/17/2025, they bought 225,000 shares at a weighted average price of $1.2248.

Following these transactions, one indirect position is shown as 62,975,000 shares, with additional direct and indirect holdings of 2,901,062, 13,939,637, and 2,744,219 shares reported for various Casdin-managed funds and Eli Casdin. The filing notes that prices are weighted averages over multiple trades within stated ranges and that the securities of several funds may be deemed beneficially owned by Casdin Capital entities and Eli Casdin.

Standard BioTools (LAB) reported insider open‑market purchases by entities affiliated with Eli Casdin. The filing lists four buys totaling 1,175,000 shares on 11/07 (225,000 at a weighted average $1.1234), 11/10 (275,000 at $1.1706), 11/11 (300,000 at $1.196), and 11/12/2025 (375,000 at $1.1889).

Following these transactions, the Master Fund’s indirectly beneficially owned balance is stated as 62,050,000 shares. Additional positions reported include 2,901,062 shares held directly by Eli Casdin, 13,939,637 shares indirectly by Casdin Private Growth Equity Fund II, L.P., and 2,744,219 shares indirectly by Casdin Private Growth Equity Fund, L.P. The form is filed by more than one reporting person and marks the reporting persons as a director and 10% owner.